Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A011502||Alliance||A Randomized Phase III Double Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial||Adult CIRB - Late Phase Emphasis||Available to Open|
|A091202||Alliance||A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist; Efatutazone in Patients with Previously Treated; Unresectable Myxoid Liposarcoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|A091401||Alliance||Randomized Phase II Study Of Nivolumab With Or Without Ipilimumab In Patients With Metastatic Or Unresectable Sarcoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|A031801||Alliance||A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RADICAL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA9161||Alliance||A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A071701||Alliance||Genomically-Guided Treatment Trial in Brain Metastases||Adult CIRB - Late Phase Emphasis||Available to Open|
|A222001||Alliance||A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy||Cancer Prevention and Control CIRB||Available to Open|
|A051301||Alliance||A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA9171||Alliance||BLAST MRD CML 1 Trial: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD||Adult CIRB - Late Phase Emphasis||Available to Open|
|A221505||Alliance||RT Charm: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction||Cancer Prevention and Control CIRB||Available to Open|